Novel Tricyclic Compounds as 5‑HT2A Receptor Agonists for Treating Depression, Anxiety, Substance Abuse, and Headaches.
Ram W. Sabnis, Anika R. Sabnis
ACS Medicinal Chemistry Letters May 7, 2026 DOI: 10.1021/acsmedchemlett.6c00235 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Peer reviewed |
|---|---|
| Topics | Anxiety Depression Serotonin |
Abstract
Provided herein are novel tricyclic compounds as 5-HT2A receptor agonists, pharmaceutical compositions, use of such compounds in treating depression, anxiety, substance abuse and headaches, and processes for preparing such compounds.
Citations in the library
Cited by 3
- Novel 6,5-Bicyclic Compounds as 5-HT2A Receptor Agonists for Treating Depression, Anxiety, Substance Abuse, and Headaches ACS Medicinal Chemistry Letters July 3, 2026
- Novel 5,6-Bicyclic Compounds as 5-HT2A Receptor Agonists for Treating Depression, Anxiety, Substance Abuse, and Headaches ACS Medicinal Chemistry Letters June 3, 2026
- Novel Tetrahydropyridinyl-6,6-Bicyclic Compounds as 5‑HT2A Receptor Agonists for Treating Depression, Anxiety, Substance Abuse, and Headaches. ACS Medicinal Chemistry Letters August 13, 2026
Cites 5
- 5-HT2A receptors: Pharmacology and functional selectivity. Pharmacological Reviews April 23, 2025
- Antidepressant and anxiolytic effects of activating 5HT2A receptors in the anterior cingulate cortex and the theoretical mechanisms underlying them - A scoping review of available literature. Brain Research 2025
- Exploring DMT: Endogenous role and therapeutic potential. Neuropharmacology May 1, 2025
- The evolution of N, N-Dimethyltryptamine: from metabolic pathways to brain connectivity. Psychopharmacology April 11, 2025
- The science of psychedelic medicine. Nature Medicine February 6, 2026